evipedia.ai
← Back

Coluracetam for Health & Longevity

Evidence Review created on 09/19/2026 using AI4L / Opus 5

Also known as: MKC-231, BCI-540

Motivation

Coluracetam (also sold as MKC-231 or BCI-540) is a laboratory-made compound from the racetam family (a group of synthetic molecules first explored for memory and learning). Unlike most of its relatives, it was built to act on the step that draws choline — a nutrient the brain converts into a signalling chemical used for attention and memory — into nerve cells.

A Japanese pharmaceutical company created the compound as a candidate treatment for Alzheimer’s disease, and a United States biotechnology firm later tested it for low mood with anxiety. Neither program reached market, and the compound moved instead into the grey market for cognitive enhancers, where it is sold as a powder and used orally in small daily doses. Its standing there rests largely on personal accounts rather than published results.

This review examines what is known about coluracetam: how it is thought to work, what the animal and human studies show and fail to show, what comes with using an unapproved compound, and how it is used in practice.

Benefits - Risks - Protocol - Conclusion

These sources give a high-level orientation to coluracetam as a nootropic (a compound used to enhance cognition) and to the choline-transport mechanism it was designed to act on.

Only four items are listed. Direct searches of all six priority expert platforms returned nothing naming coluracetam or its transporter target, so no priority-expert item qualified; the remaining eligible material was vendor promotional copy rather than substantive analysis, and padding the list with it would have lowered the quality of the section.

Grokipedia

  • Coluracetam

    The site’s dedicated entry on the compound, covering its chemistry, its passage through two pharmaceutical sponsors, the choline-uptake mechanism, and the preclinical record, with citations to the underlying literature.

Examine

  • Coluracetam

    Examine’s independent assessment concludes there is no human evidence for coluracetam and no demonstrated effect on choline uptake in undamaged neurons, and derives a dose estimate scaled from the rodent work.

ConsumerLab

No ConsumerLab article on coluracetam exists. ConsumerLab tests dietary supplements sold through retail channels, while coluracetam is an unapproved investigational drug and not a lawful dietary ingredient, so it falls outside the organization’s testing program.

Systematic Reviews

No systematic reviews or meta-analyses for Coluracetam were found on PubMed as of September 19, 2026.

Both sides of the trade-off are unrepresented: no systematic review or meta-analysis covers the claimed cognitive or mood benefit, and none covers safety or adverse effects.

Mechanism of Action

Coluracetam’s target is high-affinity choline uptake (HACU — sodium-dependent transport of choline into nerve endings, the rate-limiting step in making acetylcholine, the brain’s signalling chemical for attention, learning and memory). The transporter is CHT1 (encoded by SLC5A7, the gene setting choline recapture capacity). Rodent work shows coluracetam binds CHT1 and raises the maximum transport rate about 1.6-fold, with a 1.7-fold rise in surface transporter numbers — redirecting trafficking to the membrane rather than switching the protein on. Downstream, acetylcholine synthesis and release recover. Those reports come from Mitsubishi Tanabe Pharma’s own laboratory, which stood to profit from a favorable result.

The selectivity claim is narrow: the effect appears in tissue whose cholinergic (acetylcholine-releasing) nerve endings have been chemically injured and was absent in normal tissue. Coluracetam neither inhibits acetylcholinesterase (the enzyme that breaks acetylcholine down) nor binds muscarinic acetylcholine receptors, separating it from the cholinesterase inhibitors (drugs blocking that enzyme) used in dementia.

Two readings compete. The second sponsor argued a neurogenic action (growth of new neurons in the hippocampus, the brain’s memory hub) behind its depression program. Vendor material instead describes an ampakine action (amplifying signalling at glutamate receptors), with no published binding data.

Pharmacology: blood levels peak near 30 minutes and fall within three hours; it is fat-soluble and reaches brain tissue, yet effects persist 24 hours after brain levels are undetectable. Its metabolic route and enzymes — CYP3A4 (a liver enzyme clearing many drugs) among candidates — are unpublished.

Historical Context & Evolution

Coluracetam was synthesized as MKC-231 by Mitsubishi Tanabe Pharma and developed as a candidate treatment for Alzheimer’s disease. The rationale was the cholinergic hypothesis of dementia: if memory loss tracks the failure of acetylcholine signalling, a compound that restores the rate-limiting choline uptake step should restore memory. The program’s own animal findings were specific. In rats given a toxin that destroys cholinergic terminals, oral doses of 1–10 mg/kg restored water-maze learning without the tremor, salivation or low body temperature that high-dose tacrine (an early dementia drug) produced, and 11 days of dosing in mice restored working memory and the hippocampal acetylcholine that two comparison agents left unchanged. The same work showed the effect was absent in undamaged tissue — a limit, not a failure, and the finding that has shaped the compound’s standing since.

Human development did not reproduce this. The Alzheimer’s program stopped, the compound was licensed to the United States firm BrainCells Inc. as BCI-540, and its rationale was recast around hippocampal neurogenesis for depression with anxiety. That program ended after a single trial and the company closed in 2014.

Interest then migrated to the cognitive-enhancement community, where the compound is bought directly. Opinion has not settled: the developer’s data remain unrefuted, no independent group has replicated or contradicted them in humans, and with no patent holder and no payer — insurers and health systems reimburse nothing here, while generic cholinesterase inhibitors cost little — nobody carries a financial reason to fund the trial that would decide the question.

Expected Benefits

Coluracetam’s claimed benefits sit almost entirely in rodent and cell work; the grades below reflect that.

High 🟩 🟩 🟩

No benefit reaches High: there is no human clinical endpoint and no validated clinical surrogate for coluracetam shown in more than one trial — the only human outcome data come from a single six-week randomized trial that was never published.

Medium 🟩 🟩

No benefit reaches Medium either: that single trial missed its endpoints and posted no data, and no consistent observational human dataset on the compound exists in any form.

Low 🟩

Mood and Anxiety Symptoms in Treatment-Resistant Depression ⚠️ Conflicted

The only human trial gave 80 mg doses for six weeks to 115 adults with depression plus anxiety; a later review lists it among candidate antidepressants. It missed both main endpoints, leaving only a subgroup signal found afterward. Nothing was published, so the net reading is no demonstrated benefit.

Magnitude: Not quantified in available studies. The trial’s outcome data were never posted to the registry or published in a journal, so no effect size on any depression or anxiety scale exists in the literature.

Speculative 🟨

Subjective Focus, Motivation and Recall in Everyday Use

Users report steadier motivation, easier focus and quicker recall within weeks. No controlled study has tested enhancement in undamaged cognition; the basis is anecdotal, and the animal effect appeared only in damaged tissue.

Reversal of Chemically Induced Cholinergic Memory Deficits

In rats and mice whose cholinergic nerve endings were destroyed by a toxin, repeated oral dosing restored water-maze and working-memory performance. No human cognitive study exists.

Reversal of Drug-Induced Cognitive Deficits and Cholinergic Cell Loss

In rats given repeated phencyclidine (a drug used to model cognitive impairment), coluracetam restored object-recognition memory and protected acetylcholine-making septal neurons. Basis is a rodent model from a laboratory independent of the developer.

Protection of Neurons Against Glutamate Overexcitation

Cultured fetal rat cortical neurons exposed to glutamate or a calcium-raising agent survived better after 12–24 hours of coluracetam. The basis is cell-culture work only; no animal or human model has tested it.

Relief of Stress-Induced Visceral Pain

In rats made hypersensitive by chronic stress, spinal or oral coluracetam reduced pain responses by raising choline transporter levels and acetylcholine. Basis is rodent chronic-stress models only.

Sharper Color, Contrast and Sound Perception

Users report brighter colors, crisper contrast and sharper hearing within an hour. No controlled study has measured vision, hearing or the proposed retinal repair; the basis is anecdotal, resting on cholinergic retinal signalling.

Benefit-Modifying Factors

  • Low-capacity choline transporter variant: Carriers of the CHT1 Ile89Val variant (rs1013940, which reduces choline uptake capacity) are markedly more distractible and show greater depression severity — the group in which a transporter-directed compound is most plausible.

  • Baseline choline intake and status: The compound moves choline across a membrane; it does not create choline. Where dietary intake from eggs, liver and soy is low, the transport step is not the limiting one and any effect should be smaller.

  • Sex-based differences: No sex-stratified data on coluracetam exist. Women have lower endogenous choline synthesis before menopause and higher dietary choline requirements, which could plausibly shift response, but this remains an inference rather than a finding.

  • Pre-existing cholinergic injury: The animal effect appeared only where cholinergic terminals were damaged. That predicts more response in early neurodegenerative change or post-chemotherapy cognitive impairment than in intact cognition — untested in people either way.

  • Age at start: Choline transporter density and acetylcholine synthesis fall with age, so older adults plausibly have more headroom. Against that, the one human trial enrolled only ages 21–60, leaving adults past 60 entirely unstudied.

Potential Risks & Side Effects

The risk picture is shaped less by known toxicity than by the absence of any published human safety dataset.

High 🟥 🟥 🟥

No risk reaches High: no human adverse-event outcome and no validated clinical safety endpoint has been reported for coluracetam in more than one trial — the single randomized trial’s safety data were never posted or published.

Medium 🟥 🟥

No risk reaches Medium either: that one six-week trial in 115 adults posted no adverse-event dataset at all, and no consistent observational safety series or published case-report record for the compound exists.

Low 🟥

Exposure to Mislabeled or Adulterated Product

Cognitive-enhancement products sold over the counter were analyzed by mass spectrometry and carried undeclared unapproved drugs at pharmaceutical-level doses. Coluracetam is bought through the same unregulated channel, so label content is an assumption rather than a fact. Severity ranges from nothing to a serious drug exposure.

Magnitude: 75% (9 of 12) of declared drug quantities were inaccurate; single products exposed users to up to four-fold the typical pharmacologic dose and as many as four unapproved drugs, several of them absent from the label.

Headache, Fatigue and Cholinergic Overstimulation

Headache and fatigue are what users report most, usually easing with a lower dose or added choline; mental fog and daytime sleepiness are described alongside. The compound increases acetylcholine synthesis and release, drawing on available choline. Nausea, sweating and jaw tension follow the same pattern. Evidence is uncontrolled self-report.

Magnitude: Not quantified in available studies. No controlled trial has published an adverse-event table for coluracetam, so incidence rests entirely on unstructured user reports with no denominator.

Sleep Disruption, Irritability and Mood Worsening

Evening dosing is reported to delay sleep onset and sharpen irritability; a minority report worsened anxiety or low mood rather than relief. Procognitive effects persisted 24 hours after the drug had cleared the brain, so a three-hour half-life does not bound the effect. Evidence is uncontrolled self-report.

Magnitude: Not quantified in available studies. Neither sleep nor mood change was an endpoint in the one human trial, whose data were never posted, so no incidence figure exists.

Speculative 🟨

Accelerated Colonic Transit and Loose Stools

In healthy control rats, coluracetam raised colonic transporter levels, acetylcholine and gut motility. Basis is rodent only, but it is the one effect shown in undamaged tissue.

Transient Rise in Blood Glucose

Injection directly into rat brain ventricles raised plasma glucose far less than neostigmine did, and the authors judged the effect pharmacologically negligible. Basis is a rodent model using a route no one uses.

Unstudied Visual and Perceptual Change

Users report altered brightness and contrast; whether blurring, field loss or eye pain can follow is unmeasured. No study has examined the retina or visual pathway on coluracetam; the basis is isolated user reports.

Unstudied Effect on Blood Cell Counts

The sponsor’s trial excluded low blood counts and barred marrow-suppressing drugs, implying a concern its unpublished data never resolved. No effect on blood counts has been reported; the basis is that precaution alone.

Risk-Modifying Factors

  • Choline transporter genotype: Ile89Val carriers already run reduced uptake capacity. Whether that raises headache risk by leaving less spare choline, or lowers it by blunting the drug’s effect, is untested — genotype cuts both ways here.

  • Baseline choline and homocysteine: Low dietary choline plus a homocysteine above roughly 9 µmol/L (a marker of strained methyl-donor supply) marks the state in which cholinergic side effects are most often reported and co-supplementation most often helps.

  • Sex-based differences: No sex-stratified adverse-event data exist. Lower pre-menopausal choline synthesis in women is a theoretical reason to expect more depletion-type headache, but nothing has measured it.

  • Pre-existing conditions: Asthma, chronic obstructive pulmonary disease, peptic ulcer disease, bradycardia (a slow resting heart rate) and urinary obstruction all worsen under cholinergic load. The one human trial also excluded anyone with prior seizures.

  • Age and polypharmacy: Adults past 60 were excluded from the only trial. They also carry more anticholinergic (acetylcholine-blocking) prescriptions — bladder, sleep and antidepressant agents — whose effects this compound opposes, making interaction more likely.

Key Interactions & Contraindications

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine, huperzine A): Additive cholinergic load — caution. Consequence is nausea, a slowed heart, cramping or bronchospasm (airway tightening). Mitigation: the combination is avoided; where unavoidable, the coluracetam dose is halved and resting heart rate checked weekly.

  • Anticholinergic medications (oxybutynin, amitriptyline, diphenhydramine, scopolamine): Direct pharmacological opposition — caution. Each blunts the other, wasting both and confusing any assessment of effect. Mitigation: the full medication list is reviewed for anticholinergic burden before starting.

  • Direct cholinergic agonists (bethanechol, pilocarpine): Additive effect on the same target — caution. Consequence is sweating, salivation, abdominal cramping and low heart rate. Mitigation: dosing is separated by several hours and coluracetam started at the lowest dose.

  • Agents lowering the seizure threshold (bupropion, tramadol, high-dose theophylline): Caution, on precautionary grounds. The one human trial excluded anyone with seizure history, implying an unresolved concern. Mitigation: the combination is avoided where any seizure risk factor is present.

  • Over-the-counter anticholinergic sleep and allergy aids (diphenhydramine, doxylamine, dimenhydrinate): Caution — these directly cancel the intended effect and add next-day cognitive dulling. Mitigation: a non-anticholinergic sleep approach is substituted rather than dosing both.

  • Over-the-counter caffeine: Caution — additive stimulation reported as jitteriness and delayed sleep onset. Mitigation: total caffeine is held under roughly 200 mg on dosing days, with none within eight hours of bedtime.

  • Choline donor supplements (alpha-GPC, short for alpha-glycerophosphocholine; citicoline; choline bitartrate): Additive by design rather than by accident — monitor. Supplying substrate to a transporter-enhancing drug is community practice and the usual fix for headache. Mitigation: 150–300 mg alpha-GPC alongside dosing.

  • Other racetams (piracetam, aniracetam, oxiracetam) and nicotine: Additive cholinergic effect — monitor. Combining several cholinergic agents makes attribution of any adverse effect impossible and raises overstimulation risk. Mitigation: agents are introduced one at a time, two weeks apart.

  • Alcohol: Caution — alcohol suppresses hippocampal acetylcholine release and impairs the memory consolidation the compound targets. Mitigation: use is separated by at least the dosing day, rather than attempting a same-evening combination.

Populations who should avoid Coluracetam:

  • Pregnant or lactating women — no reproductive toxicity data of any kind exist
  • Anyone with a history of seizures of any type
  • Adults outside the only studied age range of 21–60 years
  • Known hypersensitivity to any cholinesterase inhibitor or cholinergic agonist
  • Baseline cytopenias (low blood cell counts) — hemoglobin below the laboratory reference range, absolute neutrophil count below 1.5 ×10⁹/L, or platelets below 150 ×10⁹/L
  • Symptomatic bradycardia (resting heart rate below 50 beats per minute) or second- or third-degree heart block (a partial or complete failure of the heart’s electrical signal to reach the pumping chambers)
  • Active peptic ulcer disease, or mechanical urinary or intestinal obstruction
  • Asthma or chronic obstructive pulmonary disease with active bronchospasm

Risk Mitigation Strategies

  • Third-party certificate of analysis before first use: A batch-specific mass-spectrometry or chromatography report showing identity and ≥98% purity addresses the mislabeling and adulteration risk, which is the largest quantified hazard in this review.

  • Low starting dose of 3–5 mg held for two weeks: Beginning well below every published community range surfaces headache, fatigue, nausea and irritability at a dose low enough to stop before they matter.

  • Choline substrate of 150–300 mg alpha-GPC alongside each dose: Supplying choline directly addresses the depletion-type headache users report most often, and matches the mechanism — the compound moves choline rather than producing it.

  • Dosing confined to before 14:00: Effects persisted 24 hours after brain clearance in animals, so afternoon and evening dosing is the practical cause of the reported sleep-onset delay and next-day irritability.

  • Baseline and 12-week complete blood count: The only human trial screened out low blood counts and barred drugs linked to marrow suppression, implying an unresolved hematologic question that no published data close.

  • Single-agent introduction with a two-week washout: Adding coluracetam to an existing regimen makes every adverse effect unattributable. Introducing it alone preserves the ability to identify which agent caused what.

  • Discontinuation on any visual change beyond brightness: Reported visual effects are unstudied. Blurring, field loss or pain is a stop signal rather than a dose-adjustment signal, and grounds for an ophthalmology review.

Therapeutic Protocol

  • Community standard dose: Braintropic gives a typical 5–35 mg daily and David Tomen of Nootropics Expert 20–80 mg, with 10 mg a common starting point. These are practice conventions, not validated doses.

  • Clinical-trial regimen: The sponsor’s protocol used 80 mg once daily or 80 mg three times daily for six weeks — at the top of, or far above, any community range. Neither regimen has demonstrated superiority over the other.

  • Oral versus sublingual route: Nootropics Expert describes smaller doses taken sublingually for faster absorption, alongside oral dosing with a fat-containing meal. No comparative bioavailability data exist to adjudicate between them.

  • Dose scaling from animal data: Examine’s conversion of the effective rodent range of 300–3,000 µg/kg yields roughly 3–33 mg for a 68 kg adult, which overlaps the lower community range and sits far below the trial dose.

  • Best time of day: Morning, before 14:00. Effects outlast plasma clearance, and later dosing is the consistent explanation given for delayed sleep onset in user reports.

  • Half-life: Plasma levels peak near 30 minutes and fall substantially within about three hours. The functional effect outlasts this, so half-life is a poor guide to redosing interval here.

  • Single versus split dosing: The community convention is one morning dose; the trial’s higher-exposure arm gave 80 mg three times daily rather than once. Splitting raises total daily exposure without evidence that it improves response.

  • Pairing with a choline source: 150–300 mg alpha-GPC or 250 mg citicoline (a choline compound that also supports cell membranes) is taken alongside, on the reasoning that the drug enhances transport rather than supply.

  • Genetic considerations: No pharmacogenetic dosing rule exists. CHT1 Ile89Val carriers are the group with the clearest mechanistic rationale for response; CYP-based dose adjustment is impossible, as the metabolic route is unpublished.

  • Sex-based considerations: No sex-stratified dosing data exist. Higher dietary choline requirements in women argue for attention to choline intake rather than for a different coluracetam dose.

  • Age-related considerations: Adults past 60 were excluded from the only human trial. Where used at that age, the conservative course is the bottom of the range, 3–5 mg, with closer attention to heart rate and anticholinergic co-medication.

  • Baseline biomarkers before dosing: Complete blood count, alanine aminotransferase, resting heart rate, fasting glucose and homocysteine are taken first, so that any later change has a reference point rather than an impression.

  • Pre-existing conditions: Asthma, peptic ulcer disease, bradycardia and urinary obstruction all argue against use. Existing anticholinergic prescriptions are reconciled before starting, since the two work against each other.

Discontinuation & Cycling

  • Not a lifelong intervention: Nothing supports indefinite use. The only human exposure data cover six weeks, so anything beyond that is unstudied territory rather than an established maintenance regimen.

  • No documented withdrawal syndrome: No withdrawal effects have been reported in any published source. The trial included a Physician Withdrawal Checklist at weeks 7 and 12, but those results were never released.

  • Tapering is not required pharmacologically: With a roughly three-hour half-life and no dependence signal, abrupt cessation carries no known risk. A one-week step down simply makes any loss of effect easier to attribute.

  • Cycling is the common practice: Users typically run 4–8 weeks on, then 2–4 weeks off. The rationale is receptor and transporter tolerance, which is plausible but has never been measured for this compound.

  • Persistence argues for intermittent dosing: Animal cognitive effects outlasted brain drug levels by 24 hours, which is the strongest available argument that daily dosing may be unnecessary rather than merely cautious.

  • Stop-and-reassess trigger: If no change is apparent after eight weeks at the upper community dose with adequate choline, continuing adds exposure without information. Stopping is the informative move.

Sourcing and Quality

  • Unregulated supply chain: Coluracetam is sold as a research chemical, not a supplement or medicine. No regulator inspects the manufacturing, so vendor quality controls are the only barrier between the buyer and an incorrect compound.

  • Batch-specific certificate of analysis: The informative form is a report tied to the batch number, dated, from a named independent laboratory, showing identity by mass spectrometry and purity by chromatography — not a generic manufacturer datasheet with no batch reference.

  • Purity and residual solvent limits: A useful certificate states purity ≥98%, names the analytical method, and reports residual solvents and heavy metals. Absence of these numbers is itself the finding.

  • Weighing accuracy matters at this scale: Single- and double-digit milligram doses cannot be measured with a kitchen scale. A milligram scale readable to 1 mg, or pre-weighed capsules from the vendor, prevents accidental multi-fold overdosing.

  • Vendors with published third-party testing: Suppliers in this category that publish per-batch analyses include Science.bio, Swiss Chems and Pure Nootropics. Publishing a certificate is a minimum condition, not an endorsement of any of them.

  • Compounding pharmacies are not an option: Because the compound is unapproved in every major jurisdiction, no licensed compounding pharmacy will prepare it, removing the usual route to a pharmaceutical-grade preparation.

Practical Considerations

  • Time to effect: Subjective effects are reported within 30–60 minutes of a dose, consistent with the rapid blood peak. Any durable cognitive change, if real, would need the 4–8 week timescale used in the animal repeat-dosing work.

  • Common pitfall — combining on day one: Adding coluracetam to an existing multi-compound regimen makes both benefit and adverse effect unattributable. This is the most common reason people cannot tell whether it worked.

  • Common pitfall — skipping choline: Headache is the most reported effect and the one most often resolved by adding a choline source. Dosing without one repeats a well-documented and avoidable mistake.

  • Common pitfall — chasing dose: Absence of an obvious effect prompts escalation toward the 80 mg trial dose. That dose produced no benefit in the only trial that used it, so escalation buys exposure, not effect.

  • Regulatory status: Not approved in any jurisdiction and not a lawful dietary ingredient in the United States. It is sold as a research chemical, which is a labelling convention rather than a legal category conferring safety oversight.

  • No organizational position exists: No medical society, regulator or advocacy organization has issued a position on coluracetam, so no organizational revenue interest bears on its standing — but equally, no independent body has examined it.

  • Cost and accessibility: Inexpensive and easy to obtain — typically under 50 US dollars for a multi-month supply of powder, purchased online and shipped directly. Cost is not a barrier; verified quality is.

Interaction with Foundational Habits

  • Sleep: Direct and blunting when timed late. Cholinergic activation delays sleep onset, and animal data show effects persisting 24 hours after brain clearance, so a three-hour half-life does not protect an evening dose. Dosing before 14:00 is the practical consequence. Acetylcholine also drives dream sleep, which fits reported vivid dreaming.

  • Nutrition: Direct and potentiating through choline supply. The compound enhances choline transport but does not create choline, so eggs, liver, soy and fish raise the ceiling on any effect. Alcohol works the other way, suppressing hippocampal acetylcholine release. A low-choline diet is the most likely nutritional reason for no response.

  • Exercise: Indirect, with no evidence of blunting. Nothing suggests interference with muscle growth or endurance adaptation. Acetylcholine carries the nerve signal to muscle, and users report a sharper sense of muscular control, but no study has measured strength, power or endurance on coluracetam either way.

  • Stress management: Indirect and plausibly bidirectional. The rodent work showing relief of stress-induced pain ran through the cholinergic system, which interacts with the stress response. Against that, users report irritability and agitation. No cortisol or heart-rate-variability data on the compound exist to settle the direction.

Monitoring Protocol & Defining Success

No validated monitoring protocol exists for coluracetam, so the panel below is assembled from the safety concerns the compound’s pharmacology and its one human trial imply. Baseline testing is done before the first dose and covers blood counts, liver enzymes, resting heart rate, fasting glucose and homocysteine, plus a written record of the specific cognitive or mood complaint that prompted use. Without that written baseline, any later judgement is memory against memory. Ongoing testing follows a defined cadence: resting heart rate weekly for the first four weeks, then monthly; the full blood panel repeated at 12 weeks and thereafter every 6–12 months while use continues; and the chosen symptom or cognitive scale repeated at 2 weeks, 8 weeks, then quarterly.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Complete blood count with differential Hemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 g/dL (women); absolute neutrophils 1.8–7.0 ×10⁹/L; platelets 200–400 ×10⁹/L The only human trial screened out low counts and barred drugs linked to marrow suppression Complete blood count is the standard panel of red cells, white cells and platelets. Conventional labs flag neutrophils only below 1.5 ×10⁹/L, well under the functional floor. No fasting needed
ALT 10–26 U/L (men), 8–22 U/L (women) Unregulated powders carry unknown impurities, and the liver is where such exposure shows first ALT is alanine aminotransferase, an enzyme released when liver cells are stressed. Conventional upper limits of 40–55 U/L sit far above the functional target. Pair with AST (aspartate aminotransferase, a second liver enzyme); fast 8–12 hours
Resting heart rate 55–70 beats per minute Cholinergic activity slows the heart; a downward drift signals overshoot before symptoms appear Conventional reference ranges run from 60 to 100 beats per minute, well above the functional ceiling. Measured seated after five minutes’ rest at the same time each morning. An overnight wearable average is an acceptable substitute if the device is consistent
Fasting glucose 75–86 mg/dL Rodent work showed a small central cholinergic rise in plasma glucose Conventional ranges extend to 99 mg/dL. Requires 8–12 hours fasting; best paired with HbA1c (glycated hemoglobin, a roughly three-month average of blood sugar)
Homocysteine 5–7 µmol/L Choline is consumed as a methyl donor, so heavy choline co-supplementation shifts this pathway Homocysteine is an amino acid that rises when methyl-donor metabolism is strained. Conventional labs accept up to 15 µmol/L. Fast 8–12 hours and have the sample separated promptly
Plasma free choline No established target for this use; track the change from the individual’s own baseline The drug acts on choline transport, so choline supply is the limiting input to any effect Not on routine panels; available through a specialty laboratory. Fasting sample, since values move with recent egg, liver and fish intake
Chosen symptom or cognitive scale score No established target; track the change from the individual’s own baseline, treating a 20% shift as meaningful Converts a subjective impression into a number that can be compared across months The same instrument at the same time of day each session. Self-administered, no fasting; a score taken on a poor night’s sleep is not comparable

Qualitative markers worth tracking alongside the panel:

  • Sleep onset latency and dream vividness, logged nightly for the first two weeks
  • Sustained attention on a single demanding task, and how readily background distraction breaks it
  • Word-finding and name recall in conversation
  • Mood floor and irritability, noted at the same time each day
  • Visual brightness and contrast, and any change beyond that
  • Headache frequency and its response to added choline
  • Bowel frequency and stool consistency

Emerging Research

  • No active trial of coluracetam: A registry search on 19 September 2026 found the 2008–2009 Phase 2 study NCT00621270 in 115 adults, with depression and anxiety scales as co-primary endpoints, to be the only human trial ever registered. Its results were never posted, and nothing is recruiting.

  • The transporter as a drug target: Ojiakor and Rylett (2020) map the trafficking steps that set surface transporter numbers and catalogue the few compounds that modulate them — the line of work most likely to show whether coluracetam’s proposed action generalizes to people.

  • Genotype-stratified testing: Berry et al. (2014) showed Ile89Val carriers are markedly more distractible, and Hahn et al. (2008) linked the same variant to depression severity. A trial enrolling by genotype could test whether benefit exists only in this group.

  • Evidence that could weaken the case: Bessho et al. (1996) found no uptake effect in undamaged tissue, a result the developer’s own data repeated. A trial in cognitively healthy adults is therefore the most likely place for the enhancement hypothesis to fail outright.

  • Evidence that could strengthen the case: Bessho et al. (2008) found effects persisting 24 hours after the drug left the brain, implying a durable change in transporter regulation rather than a transient one. Confirming that in a primate model would support intermittent rather than daily dosing.

  • Independent replication of the mechanism: The binding and trafficking evidence, Takashina et al. (2008), comes from the developer’s own laboratory; Choudhary et al. (2017) found no effect across four assay formats in undamaged cells. Independent testing in injured cholinergic tissue is the study that would settle it.

  • Product-quality surveillance: Cohen et al. (2021) found undeclared unapproved drugs and inaccurate label quantities across cognitive-enhancement products. Extending that surveillance to coluracetam would convert the largest practical hazard here from assumption into measurement.

Conclusion

Coluracetam is a synthetic compound built to act on a single narrow step — the movement of choline into nerve cells, which limits how much of the brain’s main memory-related signalling chemical can be made. That target is real and well characterized, and the compound does appear to bind it.

What follows from that is much thinner than the target suggests. The animal work is consistent, but the evidence for how the compound acts comes entirely from the laboratory of the company that owned it and stood to profit from a favorable result; the independent animal work that exists covers other questions and is thin. The effect showed up only in tissue that had already been chemically damaged, never in healthy tissue. The single human study, in adults with low mood and anxiety, did not meet its goals and was never published. No medical body has examined the compound at all.

The risks are shaped by that same emptiness. Headache and disturbed sleep are what people report, both manageable by lowering the dose, adding a choline source and dosing early in the day. The larger and better-measured hazard is the product itself: compounds sold through this channel frequently contain something other than what the label says.

For someone weighing this deliberately, coluracetam is an inexpensive and low-friction option resting on an evidence base that has stayed unresolved, rather than disproven, for two decades.

Top - Benefits - Risks - Protocol